Effects of dapagliflozin on serum low-density lipoprotein cholesterol and triglyceride levels

Basit Öğe Kaydı
dc.authorid0000-0002-3118-4549en_US
dc.contributor.authorGürkan, Eren
dc.date.accessioned2021-10-13T12:10:27Z
dc.date.available2021-10-13T12:10:27Z
dc.date.issued2020en_US
dc.departmentTayfur Ata Sökmen Tıp Fakültesien_US
dc.description.abstractObjective: The aim of this study is to assess the effects of dapagliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor, on serum triglyceride and low-density lipoprotein (LDL) cholesterol levels in patients with type 2 diabetes mellitus (DM).Methods: A total of 40 patients with type 2 DM, who were followed up regularly in the Endocrinology and Metabolism Out-patient Clinic of State Hospital, were evaluated retrospectively. In these patients, dapagliflozin was added to their regular treatment for glycemic control. The patients’ anthropometric measurements, glycemic regulation status, and serum LDL cho-lesterol and triglyceride levels were retrieved from the system records. A statistical analysis of drug effects was performed using the repeated measures analysis of covariance test, keeping the effects of HbA1c and body mass index (BMI) covariates constant.Results: In addition to the improvement in fasting blood glucose levels, HbA1c, and body weight of the patients, a reduction by 10 mg/dL and 43.04 mg/dL was observed in serum LDL cholesterol and triglyceride levels, respectively. The evaluation of BMI and HbA1c covariates together revealed a statistically significant reduction in triglyceride levels (p=0.032 and p=0.008, respectively).Conclusion: Besides glycemic control and weight loss, addition of dapagliflozin to the type 2 DM therapy is associated with an improvement in serum triglyceride levels, suggesting that together with other benefits, SGLT2 inhibitors appear to pro-vide an additional benefit of reducing the risk of cardiovascular diseases.en_US
dc.identifier.citationGÜRKAN E (2020). Effects of Dapagliflozin on Serum Low-Density Lipoprotein Cholesterol and Triglyceride Levels. European Journal of Therapeutics, 26(1), 76 - 80. Doi: 10.5152/EurJTher.2020.19005en_US
dc.identifier.doi10.5152/EurJTher.2020.19005en_US
dc.identifier.endpage80en_US
dc.identifier.issn2564-7784
dc.identifier.issn2564-7040
dc.identifier.issue1en_US
dc.identifier.startpage76en_US
dc.identifier.trdizinid383937en_US
dc.identifier.urihttps://dx.doi.org/10.5152/EurJTher.2020.19005
dc.identifier.urihttps://hdl.handle.net/20.500.12483/3340
dc.identifier.volume26en_US
dc.identifier.wosWOS:000521941600014en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherGaziantep Üniversitesien_US
dc.relation.ispartofEuropean Journal of Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCardiovascular diseasesen_US
dc.subjectDapagliflozinen_US
dc.subjectHyperlipidemiaen_US
dc.subjectSGLT2 inhibitoren_US
dc.titleEffects of dapagliflozin on serum low-density lipoprotein cholesterol and triglyceride levelsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Gurkan-Eren-2020.pdf
Boyut:
664.4 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu